Can I read Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2- early breast cancer: Primary results from the phase III NATALEE trial. on EtoBox?

Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2- early breast cancer: Primary results from the phase III NATALEE trial. by Dennis J. Slamon; Daniil Stroyakovskiy; Denise A. Yardley; Chiun-Sheng Huang; Peter A. Fasching; John Crown; Aditya Bardia; Stephen Chia; Seock-Ah Im; Miguel Martin; Sherene Loi; Binghe Xu; Sara A. Hurvitz; Carlos Barrios; Michael Untch; Rebecca L. Moroose; Fran Visco; Rodrigo Fresco; Tetiana Taran; Gabriel N. Hortobagyi is a Medicine article available to read on EtoBox.

What is Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2- early breast cancer: Primary results from the phase III NATALEE trial. about?

LBA500 Background: RIB + ET has demonstrated significant survival benefits in pre- and postmenopausal pts with HR+/HER2− metastatic BC. To investigate whether RIB + ET also improves outcomes in early BC (EBC), the Phase III NATALEE trial (NCT03701334) evaluated adjuvant RIB + ET in a broad population of pts with stage II or III HR+/HER2− EBC at risk for recurrence, including pts with no nodal involvement (N0). As extended duration of tx is crucial to prolong cell cycle arrest and drive more tumor cells into senescence or death, a 3-y duration of RIB tx at a dose of 400 mg was chosen to improve tolerability while maintaining efficacy. Results from a prespecified interim analysis of invasive disease–free survival (iDFS; primary endpoint) are presented. Methods: Men and pre- or postmenopausal women were randomized 1:1 to RIB (400 mg/day; 3 wk on/1 wk off for 3 y) + ET (letrozole 2.5 mg/day or anastrozole 1 mg/day, for ≥ 5 y) or ET alone. Men and premenopausal women also received goserelin. Eligible pts had an ECOG PS of 0-1 and BC anatomic stage IIA (either N0 with additional risk factors or 1-3 axillary lymph nodes [N1]), stage IIB, or stage III per AJCC (8th ed); prior (neo)adjuvant

Who reads Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2- early breast cancer: Primary results from the phase III NATALEE trial.?

Author

Dennis J. Slamon; Daniil Stroyakovskiy; Denise A. Yardley; Chiun-Sheng Huang; Peter A. Fasching; John Crown; Aditya Bardia; Stephen Chia; Seock-Ah Im; Miguel Martin; Sherene Loi; Binghe Xu; Sara A. Hurvitz; Carlos Barrios; Michael Untch; Rebecca L. Moroose; Fran Visco; Rodrigo Fresco; Tetiana Taran; Gabriel N. Hortobagyi

Publisher

American Society of Clinical Oncology (ASCO)

Published

2023

Language

EN

Field

Medicine (Health Sciences)